This article relies largely or entirely on a single source. (July 2020) |
Arginine/lysine, sold under the brand name LysaKare, is a fixed-dose combination medication used to protect the kidneys from radiation damage during cancer treatment with a radioactive medicine called lutetium (177Lu) oxodotreotide.[1] It contains L-arginine hydrochloride and L-lysine hydrochloride.[1]
| Combination of | |
|---|---|
| Arginine | Amino acid |
| Lysine | Amino acid |
| Clinical data | |
| Trade names | LysaKare |
| License data | |
| Routes of administration | Intravenous infusion |
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| KEGG | |
The most common side effects include nausea and vomiting.[1] Arginine/lysine is also associated with hyperkalaemia (high blood potassium levels), but the frequency of this side effect is not known.[1] Side effects with arginine/lysine are usually mild or moderate.[1]
Radiation from lutetium (177Lu) oxodotreotide can cause damage when the medicine passes through tubules in the kidney.[1] Arginine and lysine interfere with the passage of lutetium (177Lu) oxodotreotide through these kidney tubules.[1] As a result, the radioactive medicine leaves the body in the urine and the kidneys are exposed to less radiation.[1]
Arginine/lysine was approved for medical use in the European Union in July 2019.[1]
Medical uses
Arginine/lysine is indicated for reduction of renal radiation exposure during peptide receptor radionuclide therapy (PRRT) with lutetium (177Lu) oxodotreotide in adults.[1]
References
External links
- "Arginine". Drug Information Portal. U.S. National Library of Medicine.
- "Lysine". Drug Information Portal. U.S. National Library of Medicine.
 | This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |